The first hepatic Study biopsy #1 was performed due to the unexpected rate of disease progression through two lines of treatment prescribed for a presumed ER/PR positive, HER2-normal breast cancer based on a prior biopsy. This evidence concerns the gene ERBB2 and breast cancer.